RESPECT: Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone: Whole-Body MRI Study.
This trial is for patients with bone-only metastatic breast cancer. The trial aims to investigate the use of whole-body MRI scanning as a method of investigating treatment response of secondary cancer in the bone.
RESPECT is not investigating a new cancer treatment, so patients can be eligible irrespective of the type of treatment that they are receiving.
For further information, please contact the Mount Vernon Breast Cancer Research Unit team.
Arm 1 = Taxane + Herceptin + Pertuzumab following anthracycline-based (FEC) chemotherapy
Arm 2 = Kadcyla (a Herceptin based drug with a chemotherapy linked to it) + Pertuzumbab
For patients with locally advanced or metastatic breast cancer who have a BRCA gene mutation. This trial is comparing a parp inhibitor (Niraparib) with standard chemotherapy.
1st line endocrine therapy trial for hormone receptor positive metastatic breast cancer, using a biological therapy LEE011.
All patients will be given Letrozole (endocrine therapy) plus either LEE011 or placebo tablets.